Search - tctmd.com

Displaying 121 - 140 of 310

Sort: Relevancy | Date

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Presenter: Russell A. Brandwein, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Case #5: Suboptimal Transcatheter Treatment of Failed Prior Surgical Mitral Repair

Presenter: Stanley J. Chetcuti, Susheel K. Kodali, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

Case #4: Transseptal Transcatheter Treatment of Failed Mitral Bioprosthesis (With Tips and Tricks)

Presenter: Stanley J. Chetcuti, Susheel K. Kodali, Christian Spies

October 30, 2016

Presentation TCT 2016

Case #3: Leaflet Thrombosis Following Transcatheter Valve-in-Valve: Could It Have Been Prevented?

Presenter: Stanley J. Chetcuti, Susheel K. Kodali, Isaac George

October 30, 2016

Presentation TCT 2016

Case #2: Transcatheter Valve-in-Valve in a Patient With a Small Aortic Bioprosthesis: Optimizing Hemodynamics

Presenter: Stanley J. Chetcuti, Susheel K. Kodali, Vasilis Babaliaros

October 30, 2016

Presentation TCT 2016

Case #1: Coronary Obstruction Following Transcatheter Valve in Valve: What I Learned

Presenter: Stanley J. Chetcuti, Susheel K. Kodali, Hasan Jilaihawi

October 30, 2016

News Conference News PCR London Valves 2016

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

Presentation TVT 2016

Aspects of Managing the Coronary Artery Preservation: Case Presentation (Two Examples)

Presenter: Susheel Kodali

June 18, 2016

Presentation TVT 2016

Strategies for Program Growth: Meeting the Demands of New Indications Moving Parts and Evolving Processes for Growing Programs

Presenter: Susheel Kodali

June 18, 2016

Presentation TVT 2016

The Sentinel US Pivotal Clinical Trial Design

Presenter: Susheel Kodali

June 17, 2016

Presentation TVT 2016

Should Mild Paravalvular Regurgitation After TAVR Be Treated?

Presenter: Susheel Kodali

June 16, 2016

Presentation TVT 2016

The SAPIEN 3 TAVR System: Design Features, Special Attributes, and Brief Clinical Trial Status

Presenter: Susheel Kodali

June 16, 2016

Presentation TVT 2016

The Case for and Against Cerebral Embolic Protection During TAVR

Presenter: Susheel Kodali

June 16, 2016

Presentation Fellows 2016

The TAVR Revolution: The Future of Aortic Stenosis Therapy

Presenter: Mark Reisman, Susheel Kodali

April 17, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

Caitlin E. Cox

April 02, 2016

News Daily News

第 12 个月时女性的经导管主动脉瓣结局优于男性

Shelley Wood

February 23, 2016

News Daily News

Transcatheter Aortic Valve Outcomes Better in Women Than Men at 12 Months

Shelley Wood

February 23, 2016

Advertisement

Debate: TAVR for Low Risk Patients Is It time? YES, the Data Is Sufficient and Our Patients Want It!

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Case #5: Suboptimal Transcatheter Treatment of Failed Prior Surgical Mitral Repair

Case #4: Transseptal Transcatheter Treatment of Failed Mitral Bioprosthesis (With Tips and Tricks)

Case #3: Leaflet Thrombosis Following Transcatheter Valve-in-Valve: Could It Have Been Prevented?

Case #2: Transcatheter Valve-in-Valve in a Patient With a Small Aortic Bioprosthesis: Optimizing Hemodynamics

Case #1: Coronary Obstruction Following Transcatheter Valve in Valve: What I Learned

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Aspects of Managing the Coronary Artery Preservation: Case Presentation (Two Examples)

Strategies for Program Growth: Meeting the Demands of New Indications Moving Parts and Evolving Processes for Growing Programs

The Sentinel US Pivotal Clinical Trial Design

Should Mild Paravalvular Regurgitation After TAVR Be Treated?

The SAPIEN 3 TAVR System: Design Features, Special Attributes, and Brief Clinical Trial Status

The Case for and Against Cerebral Embolic Protection During TAVR

The TAVR Revolution: The Future of Aortic Stenosis Therapy

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

第 12 个月时女性的经导管主动脉瓣结局优于男性

Transcatheter Aortic Valve Outcomes Better in Women Than Men at 12 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content